Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome
US7470666B2 · kind B2 · utility
3Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2004 |
| Grant date | Dec 30, 2008 |
| Priority date | — |
| Expiry date | May 25, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to use of Ulinastatin and its pharmaceutical composition for treating and/or preventing Severe Acute Respiratory Syndrome (SARS). Ulinastatin is effective for treating and/or preventing SARS, particularly Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Ulinastatin is generally used as the pharmaceutical composition, preferably in the form of freeze-dried powder or aqueous solution for injection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.